# NeoADAURA (NCT04351555)

> A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04351555
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Non-Small Cell Lung Cancer
- Interventions: Osimertinib; Cisplatin; Carboplatin; Placebo; Pemetrexed
- Enrollment: 358
- Primary outcome: Major Pathological Response (MPR) - IASLC Method
- Primary outcome: Major Pathological Response (MPR) - Chemotherapy Method

## Commentary we found

- X threads: 112
- YouTube: 50
- Podcasts: 42
- X videos: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=neoadaura-nct04351555

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04351555", "email": "<work email>"}; the inbox owner confirms by the emailed link.